On June 27, 2012 FDA approved Lorcaserin for medical treatment
of obesity with BMI (Body mass index) >30 or BMI >27 in case of
associated diseases like diabetes and hypertension. Body mass index is arrived
at by dividing the weight in Kgs by square of height in meter i.e. Kg/square
meter.
It produces moderate weight loss, recommended along with
lifestyle modification and physical exercise.
This a selective stimulator of the 5 hydroxy triptamine receptors
located in brain, those in hypothalamus being stimulated bring satiety
resulting in less food intake.
There is some chance of getting cardiac valvulopathy, but
the trails showed similar incidence in comparison to placebo. However,
echocardiogram at regular intervals is recommended. Other side effects are
minor and are tolerable.
Published in Medscape...
Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!
...
Posts
